RenovoRx shares are trading higher after the company released interim data on progression-free survival from Phase 3 study of RenovoGem for pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
RenovoRx has released interim data on progression-free survival from its Phase 3 study of RenovoGem for pancreatic cancer, which has led to a rise in the company's stock.
June 29, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RenovoRx's stock is trading higher following the release of positive interim data from its Phase 3 study of RenovoGem for pancreatic cancer.
The release of positive interim data from a Phase 3 study is a significant milestone for any pharmaceutical company. This news indicates that RenovoRx's RenovoGem is showing promise in treating pancreatic cancer, which is likely to have boosted investor confidence and led to the rise in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100